Eugenia Sánchez
A5046613046- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
Hospital Universitario Ramón y Cajal
2021-2023
Both vedolizumab and ustekinumab are approved for the management of Crohn's disease [CD]. Data on which one would be most beneficial option when anti-tumour necrosis factor [anti-TNF] agents fail limited.
The impact of biologics on the risk postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack evidence more relevant for ustekinumab and vedolizumab.To evaluate PC.A retrospective study was performed 37 centres. Patients treated with within 12 weeks before surgery were considered "exposed". exposure 30-day PC infections assessed by logistic regression propensity score-matched analysis.A total 1535 surgeries 1370 patients. Of them, 711...